51-60 of 79 results
Allens advises PEP on acquisition of LifeHealthcare
Allens has advised private equity fund manager Pacific Equity Partners (PEP) in relation to the acquisition of ASX-listed LifeHealthcare Group Limited (LifeHealthcare) by Pacific Health Supplies ...
Allens helps deliver a healthy hospital outcome
Allens has advised the Plenary Health consortium on the expansion of the existing Casey Hospital through a series of transactions that closed late last week. The expansion will significantly increa ...
Allens advises financiers on Icon Group acquisition
Allens has advised Credit Suisse AG and Goldman Sachs Australia as financiers of the acquisition of the Icon Group, Australia's largest private cancer and oncology services group. The acquisition, ...
Allens lends a hand to Global Health
Allens has advised the Global Health Investment Fund ( GHIF ), a private investment fund whose mission is to finance late-stage drugs, vaccines and diagnostics for diseases that disproportionately ...
Special Report: Understanding the opportunities and navigating the legal frameworks of distributed ledger technology and blockchain
Authored by a multidisciplinary team from Allens Blockchain Reaction is designed to assist business stakeholders decision makers and in-house counsel across a variety of sectors to understand the technology and how it is being used as well as navigate the regulatory and legal opportunities and ...
High Court unanimously finds isolated genetic material not patentable
In the culmination of a hard-fought patent dispute the High Court of Australia has unanimously ruled that Myriad Genetics patent claims to isolated nucleic acid coding for the mutant or polymorphic BRCA1 polypeptide are not valid ...
Allens insights: Implementation of Australia's PCEHR system reviewed
At the end of 2013 the Federal Minister for Health announced a panel review into Australias Personally Controlled Electronic Health Record PCEHR system to consider implementation and uptake issues The subsequent report made public in May 2014 puts forward 38 recommendations to address the issues ...
Protecting innovation without patents - data exclusivity and market exclusivity
Developments in patent law and the consequential limitations on patentability for biologic medicines mean that data exclusivity and market exclusivity can be the primary protection afforded to originator biologic medicines This is most stark in the US where patent protection for biologic medicines ...
Predictive coding: the future of electronic document production?
A recent decision of the English High Court may pave the way for the use of predictive coding in large scale discovery and regulatory investigations in Australia Partners Nick Rudge and Duncan Travis Managing Associate Kate Austin and Associate Emily Giblin look at the benefits and risks of the new ...
Patent examination guidelines in the wake of Myriad
Following public consultation on proposed examination guidelines issued on 16 October 2015 the Commissioner of Patents has established a revised examination practice taking into account the High Courts decision in emDArcy v Myriad Genetics Incem Dr Trevor Davies Partner at Allens Patent amp Trade ...